
The FDA has approved Aurinia Pharmaceuticals’ LUPKYNIS (voclosporin) in combination with a background immunosuppressive therapy regimen to treat adult patients …
Canadian biotech Aurinia Pharmaceuticals has announced the topline Phase IIb trial results of its lupus nephritis (LN) treatment voclosporin, which …
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care

